A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA Approves Innovative Treatment for Pulmonary Arterial Hypertension, Expanding Pharmaceutical Company's PAH Portfolio

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Janssen underscores its commitment to bring targeted treatment options for EGFR-mutated Lung Cancer, despite low five-year survival rates for patients

U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1

Janssen Pharmaceutical targets innovative therapies for major diseases, aiming to transform patient care in AMD, multiple myeloma, and lung cancer

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count